Related references
Note: Only part of the references are listed.Sirtuin and pan-class I/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphoma
Jennifer E. Amengual et al.
BLOOD (2013)
Survival of Patients With Peripheral T-Cell Lymphoma After First Relapse or Progression: Spectrum of Disease and Rare Long-Term Survivors
Vivien Mak et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Molecular Profiling Improves Classification and Prognostication of Nodal Peripheral T-Cell Lymphomas: Results of a Phase III Diagnostic Accuracy Study
Pier Paolo Piccaluga et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
IMA: an R package for high-throughput analysis of Illumina's 450K Infinium methylation data
Dan Wang et al.
BIOINFORMATICS (2012)
Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy
Bertrand Coiffier et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
Peter D. Senter et al.
NATURE BIOTECHNOLOGY (2012)
Gene expression analysis uncovers similarity and differences among Burkitt lymphoma subtypes
Pier Paolo Piccaluga et al.
BLOOD (2011)
HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL
Matko Kalac et al.
BLOOD (2011)
Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study
Owen A. O'Connor et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma
Susan E. Bates et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Pralatrexate Is Synergistic with the Proteasome Inhibitor Bortezomib in In vitro and In vivo Models of T-Cell Lymphoid Malignancies
Enrica Marchi et al.
CLINICAL CANCER RESEARCH (2010)
Romidepsin and Belinostat Synergize the Antineoplastic Effect of Bortezomib in Mantle Cell Lymphoma
Luca Paoluzzi et al.
CLINICAL CANCER RESEARCH (2010)
Targeted treatment and new agents in peripheral T-cell lymphoma
Jasmine M. Zain et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2010)
Emerging role of epigenetic therapies in cutaneous T-cell lymphomas
Jasmine Zain et al.
EXPERT REVIEW OF HEMATOLOGY (2010)
Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources
Da Wei Huang et al.
NATURE PROTOCOLS (2009)
Evaluation of the Long-Term Tolerability and Clinical Benefit of Vorinostat in Patients With Advanced Cutaneous T-Cell Lymphoma
Madeleine Duvic et al.
CLINICAL LYMPHOMA & MYELOMA (2009)
Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma
Luca Paoluzzi et al.
BLOOD (2008)
Gene expression analysis provides a potential rationale for revising the histological grading of follicular lymphomas
Pier Paolo Piccaluga et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2008)
Gene expression analysis of Angioimmunoblastic lymphoma indicates derivation from T follicular helper cells and vascular endothelial growth factor deregulation
Pier Paolo Piccaluga et al.
CANCER RESEARCH (2007)
Phase IIB multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma
Elise A. Olsen et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets
Pier Paolo Piccaluga et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
The schedule-dependent effects of the novel antifolate pralatrexate and gemcitabine are superior to methotrexate and cytarabine in models of human non-Hodgkin's lymphoma
LE Toner et al.
CLINICAL CANCER RESEARCH (2006)
Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies
OA O'Connor et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer
WK Kelly et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Identifying biological themes within lists of genes with EASE
DA Hosack et al.
GENOME BIOLOGY (2003)
Gene Expression Omnibus: NCBI gene expression and hybridization array data repository
R Edgar et al.
NUCLEIC ACIDS RESEARCH (2002)
Share Paper
